Reviva Pharmaceuticals 2024 Corporate Presentation

Reviva Pharmaceuticals is a late-stage biopharmaceutical company developing brilaroxazine, a differentiated CNS modulator targeting schizophrenia, bipolar disorder, and other neuropsychiatric and inflammatory diseases. The lead candidate has completed a pivotal Phase 3 trial with topline extension data anticipated in Q4 2024, supported by significant addressable market opportunities exceeding $12 billion across multiple indications.